These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 9739438)
1. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Aranda E; Díaz-Rubio E; Cervantes A; Antón-Torres A; Carrato A; Massutí T; Tabernero JM; Sastre J; Trés A; Aparicio J; López-Vega JM; Barneto I; García-Conde J Ann Oncol; 1998 Jul; 9(7):727-31. PubMed ID: 9739438 [TBL] [Abstract][Full Text] [Related]
2. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. de Gramont A; Bosset JF; Milan C; Rougier P; Bouché O; Etienne PL; Morvan F; Louvet C; Guillot T; François E; Bedenne L J Clin Oncol; 1997 Feb; 15(2):808-15. PubMed ID: 9053508 [TBL] [Abstract][Full Text] [Related]
3. Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer. Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Chen PM Hepatogastroenterology; 2000; 47(36):1599-603. PubMed ID: 11149011 [TBL] [Abstract][Full Text] [Related]
4. 5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. Hejna M; Kornek GV; Raderer M; Valencak J; Weinländer G; Fiebiger W; Miholic J; Scheithauer W Ann Oncol; 1998 Dec; 9(12):1309-14. PubMed ID: 9932161 [TBL] [Abstract][Full Text] [Related]
5. A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Aranda E; Cervantes A; Dorta J; Blanco E; Fernández-Martos C; Cruz-Hernandez JJ; Carrato A; Gonzalez-Mancha R; García-Conde J; Díaz-Rubio E Cancer; 1995 Aug; 76(4):559-63. PubMed ID: 8625147 [TBL] [Abstract][Full Text] [Related]
6. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ; J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704 [TBL] [Abstract][Full Text] [Related]
7. Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Aranda E; Cervantes A; Carrato A; Fernández-Martos C; Antón-Torres A; Massutí T; Barneto I; García-Conde J; Barón JM; Díaz-Rubio E Ann Oncol; 1996 Aug; 7(6):581-5. PubMed ID: 8879371 [TBL] [Abstract][Full Text] [Related]
8. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324 [TBL] [Abstract][Full Text] [Related]
9. Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers. Sobrero A; Zaniboni A; Frassineti GL; Aschele C; Guglielmi A; Giuliani R; Ravaioli A; Lanfranco C; Caroti C; Arnoldi E; Barni S; Gallo L; Pessi MA; Turci D; Cortesi E; Grossi F; Frontini L; Piazza E; Bruzzi P; Labianca R Ann Oncol; 2000 Nov; 11(11):1413-20. PubMed ID: 11142481 [TBL] [Abstract][Full Text] [Related]
10. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. Hansen RM; Ryan L; Anderson T; Krzywda B; Quebbeman E; Benson A; Haller DG; Tormey DC J Natl Cancer Inst; 1996 May; 88(10):668-74. PubMed ID: 8627643 [TBL] [Abstract][Full Text] [Related]
11. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). Aranda E; Cervantes A; Carrato A; Antón-Torres A; Massutí T; Fernández-Martos C; Díaz-Rubio E J Infus Chemother; 1996; 6(3):118-22. PubMed ID: 9229321 [TBL] [Abstract][Full Text] [Related]
12. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients. Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009 [TBL] [Abstract][Full Text] [Related]
13. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results. Benson AB Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622 [TBL] [Abstract][Full Text] [Related]
14. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320 [TBL] [Abstract][Full Text] [Related]
15. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. Scheithauer W; Kornek G; Marczell A; Salem G; Karner J; Kovats E; Burger D; Greiner R; Pidlich J; Schneeweiss B; Raderer M; Rosen H; Depisch D J Clin Oncol; 1997 Mar; 15(3):908-14. PubMed ID: 9060527 [TBL] [Abstract][Full Text] [Related]
16. A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. Caudry M; Bonnel C; Floquet A; Marsault C; Quétin P; Pujol J; Maton O; Dujols JP; Caudry Y; Skawinski P Am J Clin Oncol; 1995 Apr; 18(2):118-25. PubMed ID: 7900703 [TBL] [Abstract][Full Text] [Related]
17. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). de Gramont A; Louvet C; André T; Tournigand C; Krulik M Eur J Cancer; 1998 Apr; 34(5):619-26. PubMed ID: 9713264 [TBL] [Abstract][Full Text] [Related]
18. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Beerblock K; Rinaldi Y; André T; Louvet C; Raymond E; Tournigand C; Carola E; Favre R; de Gramont A; Krulik M Cancer; 1997 Mar; 79(6):1100-5. PubMed ID: 9070486 [TBL] [Abstract][Full Text] [Related]
19. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group. Maiello E; Gebbia V; Giuliani F; Paoletti G; Gebbia N; Cigolari S; Fortunato S; Pedicini T; Borsellino N; Lopez M; Colucci G Ann Oncol; 2000 Aug; 11(8):1045-51. PubMed ID: 11038044 [TBL] [Abstract][Full Text] [Related]
20. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. Comella P; De Vita F; Mancarella S; De Lucia L; Biglietto M; Casaretti R; Farris A; Ianniello GP; Lorusso V; Avallone A; Cartenì G; Leo SS; Catalano G; De Lena M; Comella G Ann Oncol; 2000 Oct; 11(10):1323-33. PubMed ID: 11106123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]